Publications

  1. Ami Navon.
    Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions
    2021
    , 9
  2. Ami Navon.
    Architecture and molecular mechanism of PAN, the archaeal proteasome regulatory ATPase
    2009
    , 284
  3. Ami Navon.
    Discovery of novel proteasome inhibitors using a high-content cell-based screening system
    2009
    , 4
  4. Ami Navon.
    The 26 S proteasome: From basic mechanisms to drug targeting
    2009
    , 284
  5. Ami Navon.
    The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines
    2010
    , 285
  6. Ami Navon.
    Effect of noncompetitive proteasome inhibition on bortezomib resistance
    2010
    , 102
  7. Ami Navon.
    E3 ligases determine ubiquitination site and conjugate type by enforcing specificity on E2 enzymes
    2011
    , 286
  8. Ami Navon.
    A new autophagy-related checkpoint in the degradation of an ERAD-M target
    2011
    , 286
  9. Ami Navon.
    From ubiquitin-proteasomal degradation to CDK1 inactivation: Requirements for the first polar body extrusion in mouse oocytes
    2012
    , 26
  10. Ami Navon.
    PA28αβ reduces size and increases hydrophilicity of 20S immunoproteasome peptide products
    2014
    , 21
  11. Ami Navon.
    NADH Binds and stabilizes the 26S proteasomes independent of ATP
    2014
    , 289
  12. Ami Navon.
    Inherent asymmetry in the 26S proteasome is defined by the ubiquitin receptor RPN13
    2014
    , 289
  13. Ami Navon.
    The human otubain2-ubiquitin structure provides insights into the cleavage specificity of poly-ubiquitin-linkages
    2015
    , 10
  14. Ami Navon.
    Intracellular peptides as drug prototypes
    2022
  15. Ami Navon.
    The role of RNF149 in the pre-emptive quality control substrate ubiquitination
    2023
    , 6
  16. Ami Navon.
    Germline genetic biomarkers to stratify patients for personalized radiation treatment
    2022
    , 20
  17. Ami Navon.
    Peptidomic profiling of cerebrospinal fluid from patients with intracranial saccular aneurysms
    2021
    , 240
  18. Ami Navon.
    Ribonucleases as a novel pro-apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase
    2005
    , 23
  19. Ami Navon.
    N-linked glycosylation does not impair proteasomal degradation but affects class I major histocompatibility complex presentation
    2008
    , 283
  20. Ami Navon.
    The Direction of Protein Entry into the Proteasome Determines the Variety of Products and Depends on the Force Needed to Unfold Its Two Termini
    2012
    , 48
  21. Ami Navon.
    SQSTM1/p62-mediated autophagy compensates for loss of proteasome polyubiquitin recruiting capacity
    2017
    , 13
  22. Ami Navon.
    Hemopressin as a breakthrough for the cannabinoid field
    2021
    , 183
  23. Ami Navon.
    Thimet oligopeptidase biochemical and biological significances: Past, present, and future directions
    2020
    , 10
  24. Ami Navon.
    Polyglutamine-Related Aggregates Can Serve as a Potent Antigen Source for Cross-Presentation by Dendritic Cells
    2020
    , 205
  25. Ami Navon.
    VWA domain of S5a restricts the ability to bind ubiquitin and Ubl to the 26S proteasome
    2014
    , 25
  26. Ami Navon.
    ATP-induced structural transitions in PAN, the proteasome-regulatory ATPase complex in Archaea
    2007
    , 282
  27. Ami Navon.
    Direct proteasome binding and subsequent degradation of unspliced XBP-1 prevent its intracellular aggregation
    2010
    , 584
  28. Ami Navon.
    SUMOylation of Blimp-1 promotes its proteasomal degradation
    2011
    , 585